Lilly Commits $50M to UNICEF Partnership, Launches Oral GLP-1 Pill Foundayo
Lilly commits $50 million to UNICEF over six years to boost NCD prevention and care for over 30 million children across 21 countries. The launch of oral GLP-1 pill Foundayo complements $12 billion quarterly sales of Mounjaro and Zepbound, potentially expanding patient base beyond existing injections.
1. Partnership Overview
Eli Lilly has entered a six-year collaboration with UNICEF USA, pledging $50 million to strengthen primary healthcare systems and improve prevention, detection and management of non-communicable diseases among children in 21 low- and middle-income countries.
2. Funding Scope and NCD Focus
The initiative aims to reach over 30 million children and caregivers, targeting conditions like diabetes, congenital heart disease, sickle cell disease and childhood obesity by integrating NCD services into routine health programs and training health workers.
3. Foundayo Launch and GLP-1 Franchise
Lilly has introduced Foundayo, an oral GLP-1 therapy supplementing its injection portfolio of Mounjaro and Zepbound, which together generated over $12 billion in quarterly sales, with Foundayo expected to attract new patients and broaden market penetration.
4. Strategic Implications
The UNICEF partnership reinforces Lilly’s 150th anniversary commitment to global health and aligns with its 30x30 initiative to reach 30 million people annually, while the Foundayo launch may drive incremental revenue even as it risks modest cannibalization of existing GLP-1 products.